NeuroMetrix, Inc.

NasdaqCM NURO

NeuroMetrix, Inc. Price to Earnings Ratio (P/E) on January 14, 2025: -1.06

NeuroMetrix, Inc. Price to Earnings Ratio (P/E) is -1.06 on January 14, 2025, a -16.34% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.
  • NeuroMetrix, Inc. 52-week high Price to Earnings Ratio (P/E) is -0.72 on August 12, 2024, which is 32.18% above the current Price to Earnings Ratio (P/E).
  • NeuroMetrix, Inc. 52-week low Price to Earnings Ratio (P/E) is -1.22 on February 28, 2024, which is -15.42% below the current Price to Earnings Ratio (P/E).
  • NeuroMetrix, Inc. average Price to Earnings Ratio (P/E) for the last 52 weeks is -1.01.
Key data
Date Price to Earnings Ratio (P/E) Price to Sales Ratio (P/S) Price to Book Ratio (P/B) Dividend Yield
Market news
Loading...
NasdaqCM: NURO

NeuroMetrix, Inc.

CEO Dr. Shai N. Gozani M.D., Ph.D.
IPO Date July 22, 2004
Location United States
Headquarters 4B Gill Street
Employees 26
Sector Health Care
Industries
Description

NeuroMetrix, Inc., a healthcare company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico. Its primary marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system, a platform for the performance of nerve conduction studies. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.

Similar companies

VVOS

Vivos Therapeutics, Inc.

USD 5.06

4.33%

BJDX

Bluejay Diagnostics, Inc.

USD 3.36

-7.95%

NUWE

Nuwellis, Inc.

USD 1.05

3.96%

HSCS

Heart Test Laboratories, Inc.

USD 3.26

1.24%

SINT

Sintx Technologies, Inc.

USD 3.21

-4.46%

RSLS

ReShape Lifesciences Inc.

USD 4.66

-6.80%

StockViz Staff

January 15, 2025

Any question? Send us an email